BidaskClub Downgrades AVEO Pharmaceuticals (AVEO) to Strong Sell

BidaskClub downgraded shares of AVEO Pharmaceuticals (NASDAQ:AVEO) from a sell rating to a strong sell rating in a research note issued to investors on Tuesday.

AVEO has been the subject of a number of other reports. Zacks Investment Research lowered AVEO Pharmaceuticals from a hold rating to a sell rating in a research note on Wednesday, December 6th. Seaport Global Securities reissued a buy rating on shares of AVEO Pharmaceuticals in a research note on Friday, October 6th. B. Riley assumed coverage on AVEO Pharmaceuticals in a research note on Monday, November 13th. They set a buy rating and a $5.00 price target for the company. Finally, assumed coverage on AVEO Pharmaceuticals in a research note on Wednesday, November 15th. They set a buy rating and a $5.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of Hold and a consensus target price of $4.05.

AVEO Pharmaceuticals (NASDAQ:AVEO) opened at $3.10 on Tuesday. AVEO Pharmaceuticals has a one year low of $0.50 and a one year high of $4.24. The company has a debt-to-equity ratio of -0.32, a current ratio of 2.33 and a quick ratio of 2.33.

A number of institutional investors have recently made changes to their positions in AVEO. Vanguard Group Inc. boosted its stake in AVEO Pharmaceuticals by 48.6% during the second quarter. Vanguard Group Inc. now owns 3,551,360 shares of the biopharmaceutical company’s stock valued at $7,884,000 after buying an additional 1,162,232 shares during the last quarter. EAM Investors LLC bought a new position in AVEO Pharmaceuticals during the second quarter valued at approximately $1,979,000. Fore Research & Management LP bought a new stake in shares of AVEO Pharmaceuticals in the 2nd quarter valued at approximately $111,000. RA Capital Management LLC bought a new stake in shares of AVEO Pharmaceuticals in the 2nd quarter valued at approximately $18,727,000. Finally, Rehmann Capital Advisory Group bought a new stake in shares of AVEO Pharmaceuticals in the 3rd quarter valued at approximately $193,000. 50.91% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “BidaskClub Downgrades AVEO Pharmaceuticals (AVEO) to Strong Sell” was originally published by Community Financial News and is owned by of Community Financial News. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://www.com-unik.info/2018/01/13/bidaskclub-downgrades-aveo-pharmaceuticals-aveo-to-strong-sell.html.

About AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit